HORMONE RESISTANCE IN BREAST CANCER

Hormone-dependent breast cancer (HR+) accounts for the majority of diagnosed cases, and hormone therapy is the key treatment. However, the emergence of resistance compromises its efficacy and complicates patient management.This comprehensive book explores the molecular, genetic and microenvironmental mechanisms behind this resistance, while presenting the therapeutic advances that are revolutionizing clinical practice. From CDK4/6 inhibitors to the new SERDs, via therapies targeting the PI3K/AKT/mTOR pathways and emerging approaches such as immunotherapy, this book offers a clear, up-to-date summary of strategies for circumventing these resistances.Packed with scientific data, case studies and practical recommendations, it is aimed at oncologists, healthcare professionals and medical students, providing them with the tools they need to optimize the management of resistant RH+ breast cancers.An essential guide to understanding and tackling one of the major challenges of modern oncology.

Autorentext

Onkolog specjalizuj cy si w leczeniu raka piersi, dr Bentouati Abdelkader jest równie starszym wyk adowc z ponad dwudziestoletnim döwiadczeniem klinicznym i akademickim w tej dziedzinie.